See Today's Golden Star Stocks 🔥 Free for 7 Days See Today's Golden Star Stocks 🔥 Free for 7 Days
News Digest / Lukas Schmidt

Author: Lukas Schmidt
09:46am, Monday, Aug 19, 2024
Celcuity Inc. Posts Wider Q2 Loss but Gains Momentum with Promising Cancer Drug Trials and Strong Cash Reserves
Celcuity Inc. (NASDAQ: CELC) reported a Q2 2024 net loss of $23.7M, up from $14.6M last year. Despite challenges, the biotech firm is advancing gedatolisib in crucial trials and raised $129M for future initiatives, positioning for potential growth in the cancer treatment market.
Read More